Autolus Presents CARLYSLE Trial Preliminary Data Showing Significant B-Cell Depletion Improvement
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 1 hour ago0mins
- Clinical Trial Progress: Autolus presented preliminary data from the CARLYSLE trial at the American Society of Hematology meeting, indicating significant improvement in three patients dosed with 100 million cells, highlighting the therapy's potential in treating severe refractory systemic lupus erythematosus (srSLE).
- Safety Assessment: In the 50 million dose cohort, no dose-limiting toxicities (DLTs) or high-grade cytokine release syndrome (CRS) were observed in any patients, indicating a favorable safety profile for obe-cel and laying the groundwork for future clinical applications.
- Efficacy Metrics: In the 50 million dose group, 50% of patients achieved complete response rates (CRR) and 83% achieved deep responses, with no new disease activity observed during a 12-month follow-up, demonstrating the therapy's long-term efficacy.
- Future Trial Plans: Following the positive initial results from the CARLYSLE trial, Autolus has initiated the LUMINA trial aimed at further validating the registrational intent of obe-cel in lupus nephritis, showcasing the company's strategic positioning in the autoimmune disease sector.
AUTL.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on AUTL
Wall Street analysts forecast AUTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUTL is 7.68 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.550
Low
5.00
Averages
7.68
High
10.00
Current: 1.550
Low
5.00
Averages
7.68
High
10.00
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-04-10
Reason
Needham
Gil Blum
Price Target
$10
2025-04-10
Reiterates
Strong Buy
Reason
Truist Securities
Asthika Goonewardene
Strong Buy
Maintains
$11 → $10
2025-04-01
Reason
Truist Securities
Asthika Goonewardene
Price Target
$11 → $10
2025-04-01
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Autolus Therapeutics to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus' April R&D day.
Wells Fargo
Yanan Zhu
Buy
Maintains
$8 → $6
2025-03-21
Reason
Wells Fargo
Yanan Zhu
Price Target
$8 → $6
2025-03-21
Maintains
Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$10
2025-01-13
Reason
Needham
Gil Blum
Price Target
$10
2025-01-13
Reiterates
Strong Buy
Reason
See All Ratings
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?